Early-stage human trials of the vaccine began in April, making it one of a few to have reached that milestone.
“This not going to be an expensive vaccine,” Hill told Reuters in an interview. “It’s going to be a single-dose vaccine. It’s going to be made for global supply and it’s going to be made in many different locations. That was always our plan.” When the monkeys were exposed to the new coronavirus, the vaccine appeared to prevent damage to the lungs and kept the virus from making copies of itself there, although it was still actively replicating in the nose.
Hill said that as of this week, more than 1,000 people have been dosed in the trial – with around half getting the experimental vaccine and the other half serving as a control group. Health and disease experts say a vaccine that protects people from the new coronavirus could help end the pandemic, but finding one that works and manufacturing enough doses is a huge challenge.
Hill told Reuters the ChAdOx1 project has at least seven manufacturing sites around the world. Those include India’s Serum Institute as well as sites in Europe and China.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: malaymail - 🏆 1. / 86 Read more »